--- title: "Aurinia Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 83.22 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295104801.md" datetime: "2026-08-06T12:05:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295104801.md) - [en](https://longbridge.com/en/news/295104801.md) - [zh-HK](https://longbridge.com/zh-HK/news/295104801.md) --- # Aurinia Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 83.22 M Revenue: As of FY2026 Q2, the actual value is USD 83.22 M, beating the estimate of USD 80.48 M. EPS: As of FY2026 Q2, the actual value is USD 0.28, beating the estimate of USD 0.24. EBIT: As of FY2026 Q2, the actual value is USD 48.79 M. Aurinia Pharmaceuticals Inc. reported financial results for the three and six months ended June 30, 2026. #### Financial Results for the Three Months Ended June 30, 2026 - **Total Revenue**: Aurinia Pharmaceuticals Inc. generated $83.2 million in total revenue, marking a 19% increase from $70.0 million in the same period of 2025. - **Net Product Sales**: Net product sales were $79.4 million, up 19% from $66.6 million in the prior year period. - **License, Collaboration and Royalty Revenue**: License, collaboration, and royalty revenue increased by 12% to $3.8 million, from $3.4 million in the same period of 2025. - **Net Income**: Net income for the period was $37.4 million, a 74% increase compared to $21.5 million in the same period of 2025. - **Income from Operations**: Income from operations stood at $46,341 thousand. - **Total Operating Expenses**: Total operating expenses were $36,879 thousand. - **Cash Flows from Operating Activities**: Cash flows from operating activities increased by 19% to $52.5 million, up from $44.2 million in the same period of 2025. #### Financial Results for the Six Months Ended June 30, 2026 - **Total Revenue**: Total revenue reached $160.9 million, representing a 21% increase from $132.5 million in the same period of 2025. - **Net Product Sales**: Net product sales were $153.0 million, an increase of 21% from $126.5 million in the prior year period. - **License, Collaboration and Royalty Revenue**: License, collaboration, and royalty revenue grew by 36% to $8.0 million, from $5.9 million in the same period of 2025. - **Net Income**: Net income was $71.8 million, a 60% increase from $44.9 million in the same period of 2025. - **Income from Operations**: Income from operations was $87,763 thousand, compared to $41,930 thousand in the same period of 2025. - **Total Operating Expenses**: Total operating expenses were $73,162 thousand, down from $90,543 thousand in the same period of 2025. - Cost of revenue: $13,060 thousand, down from $15,689 thousand in 2025. - Selling, general and administrative: $45,537 thousand, down from $46,357 thousand in 2025. - Research and development: $20,520 thousand, up from $13,175 thousand in 2025. - Restructuring: $0, down from $1,647 thousand in 2025. - Other (income) expense, net: -$5,955 thousand, compared to $13,675 thousand in 2025. - **Cash Flows from Operating Activities**: Cash flows from operating activities were $85.1 million, an 87% increase from $45.5 million in the same period of 2025. - **Cash Flows from Investing Activities**: Cash flows from investing activities totaled $63,368 thousand, compared to $17,759 thousand in the same period of 2025. - Proceeds from the sale and maturities of investments: $209,000 thousand. - Purchases of investments: -$150,805 thousand. - Net cash and cash equivalents acquired in acquisition of Kezar: $5,212 thousand. - Purchases of property, equipment and intangible assets: -$39 thousand. - **Cash Flows from Financing Activities**: Cash flows from financing activities were -$48,875 thousand, compared to -$93,731 thousand in the same period of 2025. - Purchase of common shares under Share Repurchase Plan: -$74,880 thousand. - Payments of principal portion of Monoplant finance lease liability: -$7,058 thousand. - Proceeds from issuance of common shares for equity awards: $59,154 thousand. - Proceeds from issuance of common shares under ESPP: $363 thousand. - Tax withholding payments related to net settlements of equity awards: -$26,454 thousand. - **Cash Position**: As of June 30, 2026, Aurinia Pharmaceuticals Inc. had cash, cash equivalents, restricted cash, and investments totaling $443.1 million, an increase from $398.0 million at December 31, 2025. #### Outlook / Guidance Aurinia Pharmaceuticals Inc. reiterated its 2026 total revenue guidance of $315 million to $325 million, projecting an 11% to 15% increase over 2025. The company also maintained its 2026 net product sales guidance at $305 million to $315 million, anticipating a 12% to 16% increase compared to 2025. ### Related Stocks - [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md) ## Related News & Research - [Diamond Hill Capital Management LLC Investment Advisor Purchases New Position in Aurinia Pharmaceuticals Inc $AUPH](https://longbridge.com/en/news/296195979.md) - [Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug](https://longbridge.com/en/news/296500759.md) - [Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036](https://longbridge.com/en/news/296394736.md) - [Orbimed Advisors Llc Buys 625,000 Shares of BlossomHill Therapeutics (NASDAQ:BLSM) Stock](https://longbridge.com/en/news/295781248.md) - [SOA Wealth Advisors LLC. Buys 14,416 Shares of Novartis AG $NVS](https://longbridge.com/en/news/295784831.md)